Tag: MitraClip
TVT 2022: EXPAND registry shows benefit of MitraClip in patients outside of COAPT trial criteria
Analysis of the EXPAND registry, looking at one-year outcomes of MitraClip treatment in secondar...
EXPAND registry outcomes of new MitraClip devices in line with COAPT
Jörg Hausleiter (Munich, Germany) talks to Cardiovascular News about the one-year findings of ...
Virtual ACC: Newer generations of MitraClip associated with greater reduction in mitral regurgitation than previous version
Today at the American College of Cardiology/World Congress of Cardiology’s virtual scientific se...
Abbott gets green light for trial on MitraClip in moderate surgical risk patients
Abbott has announced that the US Food and Drug Administration (FDA) has approved a first-of-its-...
TCT 2019: COAPT finds MitraClip safety and efficacy is maintained at three years, and is cost-effective
The MitraClip device (Abbott) continues to demonstrate safety and efficacy at three years in pat...
ESC 2019: Two-year findings of MITRA-FR continue to show no prognosis benefit with MitraClip
At the European Society of Cardiology Congress (ESC 2019; 31 August–4 September, Paris, France),...
Fourth-generation MitraClip receives FDA approval
According to a statement, Abbott has announced it has received US Food and Drug Administration (...
PASCAL poised to rival MitraClip for safety and efficacy
PASCAL’s (Edwards Lifesciences) safety and efficacy may rival that of MitraClip (Abbott) for the...
MitraClip can be used to treat secondary mitral regurgitation in the USA
The US FDA has approved a new indication for percutaneous edge-to-edge repair (MitraClip, Abbott...
Draft NICE guidance supports use of percutaneous mitral valve repair
In draft recommendations, England’s National Institute for Health and Care Excellence (NICE) giv...
TCT 2018: Durable tricuspid regurgitation reduction with MitraClip
Data from the TriValve Registry—an international multicentre, retrospective, multidevice, regist...
TCT 2018: Audience claps as COAPT shows MitraClip reduces HF hospitalisations
Delegates at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21-25 September, ...
ESC 2018: MitraClip makes “absolutely no difference” for the prognosis of secondary mitral valve regurgitation
The first randomised controlled trial to compare percutaneous edge-to-edge repair (MitraClip, Ab...
Next-generation of MitraClip approved for use in the USA
Abbott has received approval from the US FDA for a next-generation version of its MitraClip hear...
Location of tricuspid regurgitation predicts procedural success of percutaneous edge-to-edge repair
Supporting the results of previous studies, a new study indicates that percutaneous edge-to-edge...
MitraClip becomes first approved device for transcatheter mitral valve repair in Japan
Abbott has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved its...
Millipede 50mm annuloplasty ring used in first cases
Millipede has announced the successful implantation of its newest 50mm Iris annuloplasty ring, w...
Combining MitraClip mitral valve repair with left atrial appendage occlusion is safe and feasible
Shingo Kuwata (University Heart Center, Zurich, Switzerland) and others report in Eurointerventi...
PCRLV 2016: MitraClip may be “safe and feasible” for treating tricuspid regurgitation
A first-in-man study indicates that percutaneous edge-to-edge repair with Abbott Vascular’s Mitr...
